Hormone therapy as a management strategy for lung metastasis after 5 years of endometrial cancer: A case report and literature review

Endometrial cancer patients with lung metastases are rare, and more rarely with long-term management of progesterone after recurrence. Informed consent of the patients and their families. Endometrial cancer (IVB) (Refer to 2009 FIGO stag of endometrial cancer). the patient was treated with Megestrol...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2017-12, Vol.96 (51), p.e9223-e9223
Main Authors: Zhao, Huifang, Yao, Yushuang, Yang, Hongjuan, Ma, Dehua, Chen, Aiping
Format: Article
Language:English
Subjects:
Adenocarcinoma - secondary
Adenocarcinoma - surgery
Administration, Oral
Antineoplastic Agents, Hormonal - therapeutic use
Biopsy, Needle
Clinical Case Report
Endometrial Neoplasms - diagnosis
Endometrial Neoplasms - surgery
Female
Follow-Up Studies
Humans
Hysterectomy - methods
Immunohistochemistry
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - drug therapy
Lung Neoplasms - secondary
Megestrol - therapeutic use
Middle Aged
Neoplasm Invasiveness - pathology
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Risk Assessment
Time Factors
Tomography, X-Ray Computed - methods
Treatment Outcome
Uterine Hemorrhage - diagnosis
Uterine Hemorrhage - etiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endometrial cancer patients with lung metastases are rare, and more rarely with long-term management of progesterone after recurrence. Informed consent of the patients and their families. Endometrial cancer (IVB) (Refer to 2009 FIGO stag of endometrial cancer). the patient was treated with Megestrol Acetate Dispersible Tablets (trade name Yilizhi), 160 mg, orally, once daily, without interruption. The patient has been treated with progesterone therapy for stable conditions and her survival time is already roughly a decade (December 2006-October 2016). Hormone therapy may as a long-term management for hormone receptor-positive patients with recurrent endometrial cancer.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000009223